In the last 12‑18 months the antisense oligonucleotide ASO therapeutics market has entered a rapid expansion phase, driven by a mix of high‑profile collaborations, M&A activity, and regulatory milestones. Biogen and Ionis sealed a multi‑year partnership to co‑develop ASO candidates for rare neuro‑degenerative disorders, unlocking shared data platforms that cut pre‑clinical timelines by 30 %. Meanwhile, Roche completed its acquisition of Arrowhead Pharmaceuticals’ ASO pipeline for $2.3 billion, instantly adding three late‑stage programs to its portfolio. New technology launches include Wave Life Sciences’ stereopure ASO chemistry, which received FDA Fast Track designation for a Duchenne muscular dystrophy indication, promising higher target specificity. Regulatory shifts saw the EMA introduce a streamlined assessment pathway for orphan ASO drugs, reducing review cycles from 12 to 8 months. Consumer‑driven trends are evident as patient advocacy groups push for home‑infusion kits, prompting manufacturers to expand outpatient delivery models. Finally, a $350 million Series C round led by Sequoia Capital enabled Avidity Biosciences to scale its manufacturing hub in Singapore, positioning it for global supply‑chain resilience. These developments collectively illustrate the dynamic antisense oligonucleotide aso therapeutics industry trends shaping the decade.
